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Arsenic trioxide (As2O3) is a novel anticancer agent. Daily intra-
venous infusion of 10 mg As2O3 induced complete remission in
acute promyelocytic leukaemia patients who were refractory to
conventional chemotherapy and/or all-trans retinoic acid (Shen et
al, 1997; Soignet et al, 1998). The role of arsenic in the treatment
of this unique form of leukaemia is still under investigation.
Arsenic compounds have been tested in other haematological
malignancies in vitro (Konig et al, 1997). It is not known at present
whether these compounds will prove useful in the treatment of
solid tumours. In order to investigate whether arsenic is as cyto-
toxic in acute promyelocytic leukaemia cells as in other solid
tumour cells, we screened a panel of cancer cell lines with As2O3.
Multiple mechanisms of arsenic resistance in either bacteria or
mammalian cells have been described in the literature. One of
the most important arsenic detoxification mechanisms is the
glutathione (GSH) system. Trivalent arsenic was shown to bind to
GSH in a cell free system (Scott et al, 1993). Overexpression of
glutathione-S-transferase-p (GST-p) (Lo et al, 1992), GSH (Huang
et al, 1993) or multidrug resistance-associated protein (MRP1)
(Cole et al, 1994) has been shown to confer arsenic resistance. To
investigate the correlation of the GSH detoxification system with
arsenic resistance, we examined GSH content, MRP1 and GST-p
expression in a panel of cancer cells and in multidrug-resistant
cancer cells that were cross-resistant to arsenic. L-buthionine
sulphoximine (BSO) was used to modulate cellular GSH content
and to enhance arsenic sensitivity of cancer cells.
MATERIALS AND METHODS
Cell lines
Seventeen cell lines were examined. Three cell lines were devel-
oped from patients living in an arsenic-polluted area (blackfoot
disease area). NTU-B1 was developed from a transitional bladder
carcinoma patient (Yu et al, 1992). BFTC-905 was derived from a
bladder papillary transitional cell carcinoma and BFTC-909 from
a renal pelvis transitional cell carcinoma patient (Tzeng et al,
1996). BFTC-905 and BFTC-909 were obtained from the Culture
Collection Research Center, Food Industry Research and
Development Institute, Taiwan. NB4 cells were kindly provided
by Dr H-C Hsu (Veterans General Hospital, Taipei, Taiwan).
A2780, SW620, MCF7, A172, HepG2 were kindly provided by
Dr KH Cowan (National Cancer Institute, Bethesda, MD, USA).
TSGH8302 was kindly provided by Dr Y-S Chen (Institute of
Biomedical Science, Academia Sinica, Taiwan). CL-1 cells were
provided by Dr P-C Yang (National Taiwan University Hospital,
Taiwan). NTU-B1/P14 is a cisplatin-resistant variant of NTU-B1
cells and was a gift from Dr Y-S Pu, MCF7/VP is a VP-16-resis-
tant MCF7 cells (Schneider et al, 1994) and was a gift from Dr E
Schneider (Wadworth, NY, USA). All other cell lines were
purchased from American Tissue Culture Collection (Rockville,
MD, USA).
Cytotoxicity assay
Cells were distributed in 96-well culture plates. Various concentra-
tions of As2O3 (Sigma, St Louis, MO, USA) were added to the
cells growing at 37°C in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal calf serum in triplicate. After 96 h,
the survival fraction was measured by the sulphorhodamine B
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method as described previously (Skehan et al, 1990).
Cellular GSH content
Cellular GSH content was determined by Bioxytech GSH-400
colourimetric assay kit (Oxis International, Portland, OR, USA).
Cells (106–107) were trypsinized, centrifuged and washed with
phosphate-buffered solution. Cells were then re-suspended in
500ml of ice-cold metaphosphoric acid. After homogenization, the
solution was centrifuged at 3000 g, 4°C for 10min. The clear
supernatant was collected at 4°C for further assay. Reagent R1 and
sodium hydroxide were added to the solution. After incubation at
25°C for 10min in the dark, the absorbance of the solution was
measured at 400nm. GSH concentrations in the solution were
calculated from the absorbance. Cellular GSH content is expressed
as mg of GSH mg–1 of protein.
Western blot of GST-pand MRP1
Total protein of the cells was separated by sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to polyvinylidine difluoride (PVDF) membrane. The
membrane was blocked in 5% skim milk in Tris-buffered saline,
containing 0.15% Tween for 1h before washing three times in the
same solution containing 0.01% Tween. The membrane was then
incubated with a 1:1000 dilution of polyclonal antibody against
human GST-p(Medical and Biological Laboratory, Nagoya,
Japan) for 1h. Membrane was washed and incubated with HRP-
conjugated secondary antibody. The immunolabelled protein was
detected using a chemiluminescence kit (NEN Life Science,
Boston, MA, USA).
Membrane protein was isolated from cancer cells. MRP1 levels
were measured by Western blot using 1:200 dilution of mono-
clonal antibody MRPm6 (Sanbio, Uden, The Netherlands) as
described previously (Flens et al, 1994). The immunolabelled
protein was visualized with a chemiluminescence kit (NEN Life
Science, Boston, MA, USA).
RESULTS
Cytotoxicity of As2O3 in cancer cells
Concentrations of As2O3 that inhibit 50% of cell growth (IC50s) are
listed in Table 1. Several bladder cancer (NTUB1, BFTC905, T24
and HTB-9) and gastrointestinal cancer cell lines (SW620 and
AGS) were relatively sensitive to As2O3 in addition to acute
promyelocytic leukaemic cells (NB4).
GSH content in cancer cells
GSH contents in cancer cells are shown in Table 1. To correlate
GSH contents to IC50s of nine tested cell lines, Spearman’s rho
correlative coefficient was 0.661 (P= 0.026, one-tail). Five cell
lines that were intrinsically sensitive to arsenic (IC50s < 1.5mM)
all contained a low level of GSH (GSH < 10mg mg–1 protein),
whereas four cell lines that were intrinsically resistant to
arsenic (IC50s > 1.5mM) all contained a high level of GSH (GSH
> 10mg mg–1 protein).
GST-pprotein expression in cancer cells
Overexpression of GST-pmay facilitate conjugation of trivalent
arsenic to GSH. GST-pprotein expression in the cancer cells was
measured by Western blot as shown in Figure 1. Arsenic-sensitive
NB4 cells contained very low levels of GST-pprotein. However,
several arsenic-sensitive cells, such as BFTC905 and SW620 cells,
expressed high levels of GST-pprotein, whereas arsenic-resistant
H460, Hep3B and BFTC909 cells expressed low levels of GST-p
protein. There was no correlation of GST-plevels to As2O3 IC50s in
cancer cells. Multidrug-resistant NTU-B1/P14 cells overexpressed
GST-pcompared to their drug-sensitive parental NTU-B1 cells.
MRP1 expression in cancer cells
MRP1 may facilitate export of conjugated GSH out of the cells
(Rappa et al, 1997) and thus, may affect arsenic resistance in
cancer cells. MRP1 expression in the membrane protein of cancer
cells was measured by Western blot as shown in Figure 1. H460,
BFTC909 and one multidrug-resistant MCF7/VP cell contained
measurable levels of MRP1, whereas MRP1 expression was very
low in other cancer cells. MRP1 seemed to confer resistance to
arsenic; however, not all arsenic-resistant cancer cells expressed
high levels of MRP1.
Cross-resistance of arsenic in multidrug-resistant
cancer cells
IC50s of two multidrug-resistant cancer cells are listed in Table 1.
Cisplatin-resistant NTU-B1/P14 was 5.5-fold resistant to arsenic.
Etoposide-resistant MCF7/VP cells were 4.8-fold resistant to
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Figure 1Western blot of MRP (upper lane) and GST-p(lower lane) in cancer cells. MRP (190 kDa) was expressed in measurable amount only in MCF7/VP,
BFTC909 and H460 cells. GST-p(26 kDa) was expressed in almost all cancer cells except for Hep3B cells798 C-H Yang et al
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arsenic. Glutathione content of NTU-B1/P14 was 6.7-fold higher
than that of NTU-B1 cells. On the other hand, there was no differ-
ence of GSH content between MCF7/WT and MCF7/VP cells.
MCF7/VP expressed high levels of MRP1, which may account for
its arsenic resistance, whereas NTU-B1/P14 expressed no measur-
able level of MRP1 (Figure 1).
Modulation of GSH content in cancer cells by BSO
BSO is known to deplete cellular GSH via inhibition of g-glutamyl-
cysteine synthetase, which is required for GSH biosynthesis.
NTU-B1, NTU-B1/P14, MCF7/WT and MCF7/VP cells were
incubated with various concentrations of As2O3 and 10 mM of BSO
for 4 days. Ten micromolars of BSO were not toxic to these cancer
cells (IC10s of BSO in NTU-B1, NTU-B1/P14, MCF7/WT and
MCF7/VP cells were 37 mM, > 50 mM, 27 mM and 24 mM respec-
tively). The representative cytotoxicity curves of NTU-B1 and
NTU-B1/P14 cells in As2O3 with or without co-incubation with
10 mM of BSO are shown in Figure 2. IC50s of As2O3 and GSH
contents in BSO-treated treated GSH-depleted cells (drug-sensitive
and -resistant NTU-B1 and MCF7/WT cells) are shown in Table 1.
All four cancer cells became very sensitive to arsenic (IC50s 0.1 mM
to 0.4 mM) when GSH was depleted by BSO.
DISCUSSION
Arsenic has been used widely for a long time in both Western and
Chinese medicine. The definitive role of arsenic as an anticancer
agent was not clear until a recent report for treatment of acute
promyelocytic leukaemia (Shen et al, 1997). As2O3, given as a
daily 10 mg intravenous infusion seemed to be an effective and
tolerable regimen for refractory acute promyelocytic leukaemic
patients.
Induction of partial differentiation or induction of apoptosis
have been proposed as the primary mechanism of cytotoxicity of
arsenic to acute promyelocytic leukaemic cells (Chen et al, 1997).
Due to the unique mechanism of action of arsenic to cancer cells,
the attempt to use arsenic in malignancies other than acute
promyelocytic leukaemic patients is clearly warranted (Gallagher,
1998).
In this study, bladder cancer cells NTU-B1 and BFTC905 were
most susceptible to As2O3. Apoptosis can be induced in NTU-B1
cells at 1 mM As2O3 (data not shown). IC50s of the bladder cancer
cell lines was substantially lower than reported in As2O3 peak
plasma levels (4–6 mM) in patients (Shen et al, 1997). Thus, it is
conceivable that As2O3 may be effective in the treatment of
bladder cancer and other solid tumours that show similar sensi-
tivity to arsenic.
Multiple mechanisms account for arsenic resistance in bacteria
and mammalian cells. Trivalent arsenic was shown to directly
react to reduced GSH in solution (Scott et al, 1993). The cellular
Table 1 Fifty per cent growth inhibitory concentrations (IC50s) of arsenic
trioxide on human cancer cells after 96 h of treatment
Cell lines Organ origin As2O3IC50sa GSH contentb
BFTC-905 Bladder 0.34 ± 0.03 6.03 ± 1.35
NTU-B1 Bladder 0.47 ± 0.08 7.59 ± 1.16
NTU-B1/P14 Bladder 2.59 ± 0.41 50.9 ± 10.9
NB4 Leukaemia 0.64 ± 0.11 6.12 ± 0.96
T24 Bladder 0.93 ± 0.20 ND
A2780 Ovary 1.12 ± 0.33 ND
SW620 Colon 1.16 ± 0.15 4.91 ± 0.17
AGS Stomach 1.16 ± 0.20 7.30 ± 0.84
HTB-9 Bladder 1.38 ± 0.04 ND
MCF-7 Breast 2.08 ± 0.40 28.6 ± 2.3
MCF7/VP Breast 9.89 ± 1.74 20.1 ± 0.8
TSGH8302 Cervix 2.50 ± 0.69 ND
BFTC-909 Kidney 2.84 ± 0.79 17.03 ± 2.88
H460 Lung 3.27 ± 0.49 21.84 ± 2.89
ES-2 Ovary 3.30 ± 1.36 ND
A172 Glioblastoma 3.40 ± 0.40 ND
CL-1 Lung 4.17 ± 0.50 ND
Hep3B Liver 5.17 ± 1.02 17.02 ± 1.37
HepG2 Liver 7.17 ± 1.20 ND
Co-incubation with
10 mM BSO
NTU-B1 Bladder 0.19 ± 0.04 2.28 ± 0.64
NTU-B1/P14 Bladder 0.14 ± 0.01 14.20 ± 1.59
MCF-7 Breast 0.40 ± 0.12 3.65 ± 0.23
MCF7/VP Breast 0.20 ± 0.02 2.10 ± 0.12
Shown in the Table are the means and standard errors of at least three
independent experiments. amM, bmg GSH mg–1 protein, ND: not done.
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Figure 2 Representative cytotoxicity curves of As2O3 in NTU-B1 cells (A) and NTU-B1/P14 cells (B). Cells were incubated in the presence (–n–) or absence
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arsenic content was reduced by GSH pretreatment and increased in
BSO-treated Chinese hamster ovary cells (Huang et al, 1993). It is
conceivable that cellular GSH content affects sensitivity of cancer
cells to As2O3. In this study, we have shown clearly that cancer
cells that contained low levels of GSH were all sensitive to arsenic
exposure, whereas resistant cancer cells such as lung and liver
cancer cells contained the highest amounts of GSH. Furthermore,
sensitivity of NTU-B1 and MCF7 cells to arsenic can be increased
when GSH was depleted by pretreatment with 10 mM BSO.
Cisplatin-resistant NTU-B1/P14 cells were cross-resistant to
arsenic, the GSH content of these cells was higher than in steady-
state parental cells. When GSH was depleted by BSO, resistant
cells became sensitive to arsenic treatment. BSO may also enhance
arsenic toxicity in wild-type MCF7 cells and multidrug-resistant
and MCF7/VP cells. When cellular GSH was depleted, all drug-
sensitive and multidrug-resistant cancer cells became very sensi-
tive to arsenic.
GST-p overexpression was noted in a Chinese hamster ovary
cells resistant to As2O3 (CHO/SA7) (Lo et al, 1992). It is conceiv-
able that GST-p protein levels may also affect intrinsic sensitivity to
arsenic. The GST-p level seems to play very little role, however, in
the determination of arsenic sensitivity of cancer cells in this study.
MRP1-transfected HeLa cells were resistant to several heavy
metal anions, including trivalent arsenic (Cole et al, 1994). In this
study, multidrug-resistant cancer cells such as MCF7/VP and
NTU-B1/P14 cells were cross-resistant to As2O3. MRP1 was over-
expressed in several arsenic-resistant cancer cells such as
BFTC909, H460 and MCF7/VP cells. However, MRP1 was not
expressed in meaningful amounts in intrinsically resistant MCF7,
HepB3 cells or acquired resistant NTU-B1/P14 cells. We demon-
strated complete reversal of arsenic resistance in MRP1-over-
expressing MCF7/VP cells when GSH was depleted by BSO. The
result suggests that MRP1 overexpression may not protect
cancer cells from arsenic toxicity when GSH was depleted.
Overexpression of MRP1 may contribute to arsenic resistance, but
MRP1 expression is not the main determinant of arsenic sensi-
tivity in cancer cells.
Use of As2O3 in solid tumour clinical trials is clearly warranted.
Our study suggests that GSH content in tumour cells may be the
main determinant of arsenic sensitivity. Attempts should be made
to measure tumour GSH content and correlate to arsenic response
in clinical trials. BSO was used to deplete GSH and enhance
chemosensitivity of alkylating agents (Bailey et al, 1994). The
peak plasma level of BSO in patients (4–6 mM) was much higher
than levels needed to enhance arsenic toxicity in arsenic resistant
cancer cells (10 mM). Therefore, adding BSO to arsenic treatment
may potentially be useful to reverse acquired arsenic resistance in
acute promyelocytic leukaemic patients or to treat tumours that are
intrinsically resistant to arsenic.
In conclusion, GSH content correlates well with arsenic resis-
tance in cancer cells. Depletion of cellular GSH by BSO enhanced
arsenic toxicity in both arsenic-sensitive and -resistant cancer
cells. Further animal studies and human trials evaluating arsenic as
an anticancer drug are warranted. Our study suggests that As2O3
should be tested in solid cancers, especially patients with bladder
and gastrointestinal cancer. This study suggests that measurement
and modulation of cellular GSH content in cancer cells should be
deployed in designing future clinical trials.
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